Entity Central Index Key
Cover [Abstract]
Document Type
Document Type
Amendment Flag
Amendment Flag
Document Period End Date
Document Period End Date
Document Fiscal Year Focus
Document Fiscal Year Focus
Document Fiscal Period Focus
Document Fiscal Period Focus
Document Annual Report
Document Annual Report
Document Transition Report
Document Transition Report
Entity Registrant Name
Entity Registrant Name
Entity Central Index Key
Current Fiscal Year End Date
Current Fiscal Year End Date
Entity Well-known Seasoned Issuer
Entity Well Known Seasoned Issuer
Entity Current Reporting Status
Entity Current Reporting Status
Entity Voluntary Filers
Entity Voluntary Filers
Entity Filer Category
Entity Filer Category
Entity Small Business
Entity Small Business
Entity Emerging Growth Company
Entity Emerging Growth Company
Entity Ex Transition Period
Entity Ex Transition Period
ICFR Auditor Attestation Flag
Icfr Auditor Attestation Flag
Entity Shell Company
Entity Shell Company
Entity Common Stock, Shares Outstanding
Entity Common Stock Shares Outstanding
Entity Public Float
Entity Public Float
Entity Interactive Data Current
Entity Interactive Data Current
Entity File Number
Entity File Number
Entity Tax Identification Number
Entity Tax Identification Number
Entity Address, Address Line One
Entity Address Address Line1
Entity Address, City or Town
Entity Address City Or Town
Entity Address, State or Province
Entity Address State Or Province
Entity Address, Postal Zip Code
Entity Address Postal Zip Code
City Area Code
City Area Code
Local Phone Number
Local Phone Number
Entity Incorporation, State or Country Code
Entity Incorporation State Country Code
Title of 12(b) Security
Security12b Title
Trading Symbol
Trading Symbol
Security Exchange Name
Security Exchange Name
Accrued and other current liabilities.
Statement Of Financial Position [Abstract]
Assets
Assets [Abstract]
Current assets:
Assets Current [Abstract]
Cash and cash equivalents
Cash And Cash Equivalents At Carrying Value
Accounts receivable
Accounts Receivable Net Current
Prepaid expenses and other current assets (includes $169 and $149 at December 31, 2020 and 2019, respectively, attributable to related parties)
Prepaid Expense And Other Assets Current
Total current assets
Assets Current
Property and equipment, net
Property Plant And Equipment Net
Other assets
Other Assets Noncurrent
Total assets
Assets
Liabilities, Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)
Liabilities And Stockholders Equity [Abstract]
Current liabilities
Liabilities Current [Abstract]
Accounts payable
Accounts Payable Current
Accrued and other current liabilities
Accrued And Other Current Liabilities
Deferred revenue (includes $0 and $1,122 at December 31, 2020 and 2019, respectively, attributable to related parties)
Contract With Customer Liability Current
Total current liabilities
Liabilities Current
Deferred revenue, net of current portion (includes $0 and $4,015 at December 31, 2020 and 2019, respectively, attributable to related parties)
Contract With Customer Liability Noncurrent
Derivative liability
Derivative Liabilities Noncurrent
Other liabilities
Other Liabilities Noncurrent
Total liabilities
Liabilities
Commitments and contingencies (Note 8)
Commitments And Contingencies
Redeemable convertible preferred stock, $0.0001 par value; 0 and 7,375,638 shares authorized shares at December 31, 2020 and 2019, respectively; 0 and 7,375,631 shares issued and outstanding at December 31, 2020 and 2019, respectively. Liquidation value of $0 and $108,596 at December 31, 2020 and 2019, respectively.
Temporary Equity Carrying Amount Attributable To Parent
Stockholders’ equity (deficit)
Stockholders Equity [Abstract]
Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of December 31, 2020 and no shares authorized as of December 31, 2019; no shares issued and outstanding as of December 31, 2020 and 2019, respectively.
Preferred Stock Value
Common stock, $0.0001 par value, 300,000,000 and 50,000,000 shares authorized at December 31, 2020 and 2019, respectively; 26,681,983 and 5,178,955 shares issued and outstanding at December 31, 2020 and 2019, respectively.
Common Stock Value
Additional paid-in-capital
Additional Paid In Capital Common Stock
Accumulated deficit
Retained Earnings Accumulated Deficit
Total stockholders’ equity (deficit)
Stockholders Equity
Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit)
Liabilities And Stockholders Equity
Due from related parties, current
Due From Related Parties Current
Due to related parties, current
Due To Related Parties Current
Due to related parties, noncurrent
Due To Related Parties Noncurrent
Temporary equity, Par Value
Temporary Equity Par Or Stated Value Per Share
Temporary equity, shares authorized
Temporary Equity Shares Authorized
Temporary equity, shares issued
Temporary Equity Shares Issued
Temporary equity, shares outstanding
Temporary Equity Shares Outstanding
Temporary equity, liquidation preference
Temporary Equity Liquidation Preference
Preferred stock, par value
Preferred Stock Par Or Stated Value Per Share
Preferred stock, shares authorized
Preferred Stock Shares Authorized
Preferred stock, shares issued
Preferred Stock Shares Issued
Preferred stock, shares outstanding
Preferred Stock Shares Outstanding
Common stock, par value
Common Stock Par Or Stated Value Per Share
Common stock, shares authorized
Common Stock Shares Authorized
Common stock, shares, issued
Common Stock Shares Issued
Common stock, shares, outstanding
Common Stock Shares Outstanding
Income Statement [Abstract]
Revenue:
Revenues [Abstract]
Collaboration and license revenue
Revenue From Contract With Customer Excluding Assessed Tax
Collaboration and license revenue, related parties
Revenue From Related Parties
Total revenue
Revenues
Operating expenses:
Operating Expenses [Abstract]
Research and development (includes $579 and $350 for the years ended December 31, 2020 and 2019, respectively, attributable to related parties)
Research And Development Expense Excluding Acquired In Process Cost
Acquired in-process research and development, related parties
Research And Development In Process
General and administrative
General And Administrative Expense
Total operating expenses
Operating Expenses
Loss from operations
Operating Income Loss
Other income (expense):
Nonoperating Income Expense [Abstract]
Interest income
Investment Income Interest
Other income (expense), net
Other Nonoperating Income Expense
Total other income (expense)
Nonoperating Income Expense
Net loss and comprehensive loss
Net Income Loss
Net loss per share attributable to common stockholders, basic and diluted
Earnings Per Share Basic And Diluted
Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic and diluted
Weighted Average Number Of Share Outstanding Basic And Diluted
Research and development expense related party.
Research and development expense, related party
Research And Development Expense Related Party
Temporary equity stock issued during period shares new issues.
Temporary equity stock issued during period shares conversion of convertible securities.
Temporary equity stock issued during period value conversion of convertible securities.
Adjustments to additional paid in capital vesting of stock warrant issued for services.
Statement Of Stockholders Equity [Abstract]
Statement [Table]
Statement [Table]
Equity Components
Statement Equity Components [Axis]
Equity Component
Equity Component [Domain]
Common Stock
Common Stock [Member]
Additional Paid-in Capital
Additional Paid In Capital [Member]
Accumulated Deficit
Retained Earnings [Member]
Cumulative Effect, Period of Adoption
Cumulative Effect Period Of Adoption [Axis]
Cumulative Effect, Period of Adoption
Cumulative Effect Period Of Adoption [Domain]
Cumulative Effect, Period of Adoption, Adjustment
Cumulative Effect Period Of Adoption Adjustment [Member]
Statement [Line Items]
Statement [Line Items]
Stockholders’ Equity (Deficit), beginning balances
Redeemable Convertible Preferred Stock, beginning balances (in shares)
Redeemable Convertible Preferred Stock, beginning balances
Stockholders’ Equity (Deficit), beginning balances (in shares)
Shares Outstanding
Accounting Standards Update [Extensible List]
Accounting Standards Update Extensible List
Issuance of redeemable convertible preferred stock, net of $3,138 of issuance cost
Temporary Equity Stock Issued During Period Value New Issues
Issuance of redeemable convertible preferred stock, net of $3,138 of issuance cost (in shares)
Temporary Equity Stock Issued During Period Shares New Issues
Conversion of redeemable convertible preferred stock into common stock
Stock Issued During Period Value Conversion Of Convertible Securities
Conversion of redeemable convertible preferred stock into common stock (in shares)
Stock Issued During Period Shares Conversion Of Convertible Securities
Conversion of redeemable convertible preferred stock into common stock
Temporary Equity Stock Issued During Period Value Conversion Of Convertible Securities
Conversion of redeemable convertible preferred stock into common stock (in shares)
Temporary Equity Stock Issued During Period Shares Conversion Of Convertible Securities
Issuance of common stock upon initial public offering, net of $17,468 issuance cost
Stock Issued During Period Value New Issues
Issuance of common stock upon initial public offering, net of $17,468 issuance cost (in shares)
Stock Issued During Period Shares New Issues
Issuance of common stock upon exercise of stock options
Stock Issued During Period Value Stock Options Exercised
Issuance of common stock upon exercise of stock options (in shares)
Stock Issued During Period Shares Stock Options Exercised
Stock-based compensation
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
Vesting of common stock warrant issued for services
Adjustments To Additional Paid In Capital Vesting Of Stock Warrant Issued For Services
Net loss
Stockholders’ Equity (Deficit), ending balances
Redeemable Convertible Preferred Stock, ending balances (in shares)
Redeemable Convertible Preferred Stock, ending balances
Stockholders’ Equity (Deficit), ending balances (in shares)
Temporary equity, issuance cost
Sale of Stock
Subsidiary Sale Of Stock [Axis]
Sale of Stock
Sale Of Stock Name Of Transaction [Domain]
Initial Public Offering
I P O [Member]
Issuance of redeemable convertible preferred stock, issuance cost
Temporary Equity Issuance Cost
Issuance of common stock upon initial public offering, issuance cost
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
Vesting of common stock warrant in return for services.
Write off of public offering costs.
Unpaid offering costs.
Statement Of Cash Flows [Abstract]
Cash flows from operating activities
Net Cash Provided By Used In Operating Activities [Abstract]
Net loss
Profit Loss
Adjustments to reconcile net loss to net cash used in operating activities
Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]
Stock-based compensation expense
Share Based Compensation
Vesting of common stock warrant in return for services
Vesting Of Common Stock Warrant In Return For Services
Change in fair value of derivative liability
Increase Decrease In Derivative Liabilities
Depreciation and amortization
Depreciation And Amortization
(Gain) loss on disposition of property and equipment
Gain Loss On Sale Of Property Plant Equipment
Write-off of public offering costs
Write Off Of Public Offering Costs
In-process research and development acquired and expensed in non-monetary related party transaction
Changes in operating assets and liabilities
Increase Decrease In Operating Capital [Abstract]
Accounts receivable
Increase Decrease In Accounts Receivable
Prepaid expenses and other current assets
Increase Decrease In Prepaid Deferred Expense And Other Assets
Other assets
Increase Decrease In Other Noncurrent Assets
Accounts payable
Increase Decrease In Accounts Payable
Accrued and other liabilities
Increase Decrease In Accrued Liabilities
Deferred revenue
Increase Decrease In Contract With Customer Liability
Net cash used in operating activities
Net Cash Provided By Used In Operating Activities
Cash flows from investing activities
Net Cash Provided By Used In Investing Activities [Abstract]
Acquisition of property and equipment
Payments To Acquire Property Plant And Equipment
Net cash used in investing activities
Net Cash Provided By Used In Investing Activities
Cash flows from financing activities
Net Cash Provided By Used In Financing Activities [Abstract]
Issuance of redeemable convertible preferred stock, net of issuance costs
Proceeds From Issuance Of Convertible Preferred Stock
Issuance of common stock in initial public offering, net of issuance costs
Proceeds From Issuance Initial Public Offering
Issuance of common stock upon exercise of stock options
Proceeds From Stock Options Exercised
Net cash provided by (used in) financing activities
Net Cash Provided By Used In Financing Activities
Net increase (decrease) in cash and cash equivalents
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
Cash and cash equivalents, beginning of period
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
Cash and cash equivalents, end of period
Supplemental disclosures of non-cash investing and financing information
Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]
Conversion of redeemable convertible preferred stock into common stock
Conversion Of Stock Amount Converted1
Purchases of property and equipment in accounts payable and accrued and other liabilities
Capital Expenditures Incurred But Not Yet Paid
Unpaid offering costs
Unpaid Offering Costs
Documents Incorporated by Reference
Documents Incorporated By Reference [Text Block]
Organization Consolidation And Presentation Of Financial Statements [Abstract]
The Company
Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]
Accounting Policies [Abstract]
Summary of Significant Accounting Policies
Significant Accounting Policies [Text Block]
Fair Value Disclosures [Abstract]
Fair Value Measurements
Fair Value Disclosures [Text Block]
Property Plant And Equipment [Abstract]
Property and Equipment, Net
Property Plant And Equipment Disclosure [Text Block]
Accrued and other liabilities.
Payables And Accruals [Abstract]
Accrued and Other Liabilities, Current and Noncurrent
Accrued And Other Liabilities [Text Block]
Research and Collaboration Arrangements.
Research And Collaboration Arrangements [Abstract]
Research and Collaboration Arrangements
Collaborative Arrangement Disclosure [Text Block]
License arrangements.
License arrangements.
License Arrangements [Abstract]
License Arrangements
License Arrangements [Text Block]
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies
Commitments And Contingencies Disclosure [Text Block]
Income Tax Disclosure [Abstract]
Income Taxes
Income Tax Disclosure [Text Block]
Temporary equity disclosure.
Temporary Equity Disclosure [Abstract]
Redeemable Convertible Preferred Stock
Temporary Equity Disclosure [Text Block]
Equity [Abstract]
Common Stock
Stockholders Equity Note Disclosure [Text Block]
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-based Compensation
Disclosure Of Compensation Related Costs Share Based Payments [Text Block]
Common stock warrants.
Common Stock Warrants
Common Stock Warrants [Text Block]
Earnings Per Share [Abstract]
Net Loss Per Share Attributable to Common Stockholders
Earnings Per Share [Text Block]
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivative Liability
Derivative Instruments And Hedging Activities Disclosure [Text Block]
Related Party Transactions [Abstract]
Related Party Transactions
Related Party Transactions Disclosure [Text Block]
Compensation And Retirement Disclosure [Abstract]
401(K) Plan
Defined Contribution Plan [Text Block]
Basis of Presentation
Basis Of Accounting Policy Policy [Text Block]
Use of Estimates and Judgements
Use Of Estimates
Segment Information
Segment Reporting Policy Policy [Text Block]
Concentration of Credit Risk
Concentration Risk Credit Risk
Cash and Cash Equivalents
Cash And Cash Equivalents Policy [Text Block]
Other risks and uncertainties.
Other Risks and Uncertainties
Other Risks And Uncertainties Policy Policy [Text Block]
Fair Value Measurements
Fair Value Measurement Policy Policy [Text Block]
Accounts Receivable—Allowance for Doubtful Accounts
Receivables Trade And Other Accounts Receivable Allowance For Doubtful Accounts Policy
Property and Equipment, Net
Property Plant And Equipment Policy [Text Block]
Impairment of Long-Lived Assets
Impairment Or Disposal Of Long Lived Assets Policy [Text Block]
Redeemable convertible preferred stock.
Redeemable Convertible Preferred Stock
Redeemable Convertible Preferred Stock Policy Policy [Text Block]
Common stock warrants.
Common Stock Warrants
Common Stock Warrants Policy Policy [Text Block]
Revenue Recognition
Revenue Recognition Policy [Text Block]
Research and Development Expenses
Research And Development Expense Policy
Accrued research and development.
Accrued Research and Development
Accrued Research And Development Policy Policy [Text Block]
Stock-Based Compensation
Compensation Related Costs Policy [Text Block]
Income Taxes
Income Tax Policy [Text Block]
Embedded Derivative
Derivatives Policy [Text Block]
Deferred offering costs.
Deferred Offering Costs
Deferred Offering Costs Policy Policy [Text Block]
Net Loss Per Share Attributable to Common Stockholders
Earnings Per Share Policy [Text Block]
Recent Accounting Pronouncements
New Accounting Pronouncements Policy Policy [Text Block]
Schedule of Concentration of Risk
Schedules Of Concentration Of Risk By Risk Factor [Text Block]
Schedule of Revenues by Geographic Region
Revenue From External Customers By Geographic Areas Table [Text Block]
Fair Value Hierarchy for Financial Assets and Financial Liabilities Measured at Fair Value on Recurring Basis
Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]
Summary of Changes in Fair Value of Level 3 Financial Instruments
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]
Schedule of Property and Equipment, Net
Property Plant And Equipment [Text Block]
Summary of Accrued Liabilities
Schedule Of Accrued Liabilities Table [Text Block]
Summary of Other Liabilities, Noncurrent
Other Noncurrent Liabilities Table [Text Block]
Schedule of collaboration and license revenue.
Summary of Collaboration and License Revenue
Schedule Of Collaboration And License Revenue Table [Text Block]
Summary of Deferred Revenue
Deferred Revenue By Arrangement Disclosure [Text Block]
Summary of Future Minimum Commitments Under Lease Contracts
Lessee Operating Lease Liability Maturity Table [Text Block]
Schedule of Effective Tax Rate of Income Tax Expense (Benefit) Differs from Federal Statutory Rate
Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]
Schedule of Tax Effects of Temporary Differences to Significant Components of Deferred Taxes
Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]
Reconciliation of Beginning and Ending Unrecognized Tax Benefits
Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]
Summary of Redeemable Convertible Preferred Stock
Temporary Equity Table [Text Block]
Schedule of common share reserved for future issuance.
Schedule of Common Share Reserved for Future Issuance
Schedule Of Common Share Reserved For Future Issuance
Summary of Stock Options Activity
Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]
Summary of Stock Compensation Expense for Employees and Nonemployees by Function
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]
Schedule of Assumptions Used in Black-Scholes Valuation Model to Estimate Fair Value of Stock Options
Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]
Computation of Basic and Diluted Net Loss Per Share
Schedule Of Weighted Average Number Of Shares Table [Text Block]
Outstanding Shares of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]
Common stock shares issued upon underwriters exercise of overallotment option.
Organization and nature of business.
Organization and nature of business.
Organization And Nature Of Business [Table]
Organization And Nature Of Business [Table]
Class of Stock
Statement Class Of Stock [Axis]
Class of Stock
Class Of Stock [Domain]
Convertible Preferred Stock
Convertible Preferred Stock [Member]
Subsequent Event Type
Subsequent Event Type [Axis]
Subsequent Event Type
Subsequent Event Type [Domain]
Subsequent Event
Subsequent Event [Member]
Organization And Nature Of Business [Line Items]
Organization And Nature Of Business [Line Items]
Number of shares sold and issued
Stock sold and issued price per share
Shares Issued Price Per Share
Common stock issued upon underwriters exercise of overallotment option
Common Stock Shares Issued Upon Underwriters Exercise Of Overallotment Option
Aggregate net proceeds, after deducting underwriting discounts and commissions and offering costs
Proceeds From Issuance Of Common Stock
Number shares issued upon conversion of redeemable convertible preferred shares
Convertible Preferred Stock Shares Issued Upon Conversion
Outstanding shares of redeemable convertible preferred stock
Accumulated deficit
Summary of significant accounting policies line items.
Summary of significant accounting policies.
Summary Of Significant Accounting Policies [Table]
Summary Of Significant Accounting Policies [Table]
Statistical Measurement
Range [Axis]
Statistical Measurement
Range [Member]
Minimum
Minimum [Member]
Maximum
Maximum [Member]
Accounting Standards Update
Adjustments For New Accounting Pronouncements [Axis]
Accounting Standards Update
Type Of Adoption [Member]
ASU 2014-09
Accounting Standards Update201409 [Member]
ASU 2018-07
Accounting Standards Update201807 [Member]
ASU 2018-13
Accounting Standards Update201813 [Member]
Balance Sheet Location
Balance Sheet Location [Axis]
Balance Sheet Location
Balance Sheet Location [Domain]
Deferred revenue.
Deferred Revenue
Deferred Revenue [Member]
ASU 2017-11
Accounting Standards Update201711 [Member]
Summary Of Significant Accounting Policies [Line Items]
Summary Of Significant Accounting Policies [Line Items]
Number of reportable segments
Number Of Reportable Segments
Number of operating segments
Number Of Operating Segments
Number of financial institutions where cash is held.
Number of financial institutions cash is held
Number Of Financial Institutions Where Cash Is Held
Concentration Risk [Table]
Concentration Risk [Table]
Concentration Risk Benchmark
Concentration Risk By Benchmark [Axis]
Concentration Risk Benchmark
Concentration Risk Benchmark [Domain]
Revenue
Sales Revenue Net [Member]
Concentration Risk Type
Concentration Risk By Type [Axis]
Concentration Risk Type
Concentration Risk Type [Domain]
Customer Concentration Risk
Customer Concentration Risk [Member]
Customer
Major Customers [Axis]
Customer
Name Of Major Customer [Domain]
Customer A.
Customer A
Customer A [Member]
Accounts Receivable
Accounts Receivable [Member]
Credit Concentration Risk
Credit Concentration Risk [Member]
Customer B.
Customer B
Customer B [Member]
Concentration Risk [Line Items]
Concentration Risk [Line Items]
Concentration risk, percentage
Concentration Risk Percentage1
Schedule Of Revenues From External Customers And Long Lived Assets [Table]
Schedule Of Revenues From External Customers And Long Lived Assets [Table]
Geographical
Statement Geographical [Axis]
Geographical
Segment Geographical [Domain]
Australia
AUSTRALIA
Netherlands
NETHERLANDS
Switzerland
SWITZERLAND
United States
UNITED STATES
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues
Allowance for doubtful accounts
Allowance For Doubtful Accounts Receivable Current
Write-offs relating to uncollectible accounts receivable
Allowance For Doubtful Accounts Receivable Write Offs
Property and equipment, estimated useful life
Property Plant And Equipment Useful Life
Impairments of long-lived assets
Impairment Of Long Lived Assets Held For Use
Change in accounting principle, accounting standards update, adopted
Change In Accounting Principle Accounting Standards Update Adopted
Change in accounting principle, accounting standards update, adoption date
Change In Accounting Principle Accounting Standards Update Adoption Date
Stockholders' equity attributable to parent
Change in accounting principle, accounting standards update, immaterial effect
Change In Accounting Principle Accounting Standards Update Immaterial Effect
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]
Measurement Frequency
Fair Value By Measurement Frequency [Axis]
Measurement Frequency
Fair Value Measurement Frequency [Domain]
Fair Value on Recurring Basis
Fair Value Measurements Recurring [Member]
Fair Value Hierarchy and NAV
Fair Value By Fair Value Hierarchy Level [Axis]
Fair Value Hierarchy and NAV
Fair Value Measurements Fair Value Hierarchy [Domain]
Level 1
Fair Value Inputs Level1 [Member]
Level 2
Fair Value Inputs Level2 [Member]
Level 3
Fair Value Inputs Level3 [Member]
Asset Class
Fair Value By Asset Class [Axis]
Asset Class
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]
Money Market Funds
Money Market Funds [Member]
Liability Class
Fair Value By Liability Class [Axis]
Fair Value by Liability Class
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]
Derivative Liability
Derivative Financial Instruments Liabilities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets
Assets Fair Value Disclosure
Liabilities
Financial Liabilities Fair Value Disclosure
Assets, Level 1 to Level 2 transfers
Fair Value Assets Level1 To Level2 Transfers Amount
Assets, Level 2 to Level 1 Transfers
Fair Value Assets Level2 To Level1 Transfers Amount
Assets, Transfers into Level 3
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
Assets, Transfers out of Level 3
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
Liabilities, Level 1 to Level 2 transfers
Fair Value Liabilities Level1 To Level2 Transfers Amount
Liabilities, Level 2 to Level 1 transfers
Fair Value Liabilities Level2 To Level1 Transfers Amount
Liabilities, Transfers into Level 3
Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
Liabilities, Transfers out of Level 3
Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
Change in fair value included in other income (expense), net
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement of Income [Extensible List]
Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
Ending Balance
Schedule Of Property Plant And Equipment [Table]
Schedule Of Property Plant And Equipment [Table]
Long-Lived Tangible Asset
Property Plant And Equipment By Type [Axis]
Long-Lived Tangible Asset
Property Plant And Equipment Type [Domain]
Machinery and Equipment
Machinery And Equipment [Member]
Leasehold Improvements
Leasehold Improvements [Member]
Furniture and Fixtures
Furniture And Fixtures [Member]
Office Equipment
Office Equipment [Member]
Computer Equipment and Software
Computer Equipment [Member]
Construction in Progress
Construction In Progress [Member]
Property Plant And Equipment [Line Items]
Property Plant And Equipment [Line Items]
Total property and equipment
Property Plant And Equipment Gross
Less: Accumulated depreciation and amortization
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
Property and equipment, net
Depreciation expense
Depreciation
Accrued clinical and preclinical study costs.
Payroll and related
Employee Related Liabilities Current
Accrued clinical and preclinical study costs
Accrued Clinical And Preclinical Study Costs
Consulting and professional
Accrued Professional Fees Current
Other accrued expenses
Other Accrued Liabilities Current
Total accrued and other current liabilities
Deferred rent, noncurrent
Deferred Rent Credit Noncurrent
Other payable, noncurrent
Other Sundry Liabilities Noncurrent
Total other liabilities, noncurrent
Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]
Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]
Product and Service
Product Or Service [Axis]
Product and Service
Products And Services [Domain]
Collaboration and License Revenue.
Collaboration and License Revenue
Collaboration And License Revenue [Member]
Counterparty Name
Counterparty Name [Axis]
Counterparty Name
Repurchase Agreement Counterparty Name [Domain]
uniQure biopharma B.V.
uniQure
Uni Qure Biopharma B V [Member]
Benitec Biopharma Limited.
Benitec
Benitec Biopharma Limited [Member]
Choroideremia Research Foundation.
CRF
Choroideremia Research Foundation [Member]
F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.
Roche
F Hoffmann La Roche Ltd And Hoffmann La Roche Inc [Member]
Cystic Fibrosis Foundation [Member]
CFF
Cystic Fibrosis Foundation [Member]
AstraZeneca.
AstraZeneca
Astra Zeneca [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration and license revenue
Deferred revenue
Contract With Customer Liability
Collaborative Arrangement and Arrangement Other than Collaborative
Type Of Arrangement [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative
Arrangements And Nonarrangement Transactions [Member]
uniQure Agreement.
uniQure Agreement
Uni Qure Agreement [Member]
Amended uniQure agreement.
Amended uniQure Agreement
Amended Uni Qure Agreement [Member]
Deferred revenue
Collaborative arrangement, initial research term.
Collaborative arrangement, initial research term
Collaborative Arrangement Initial Research Term
Upfront payment received.
Collaborative arrangement research and development milestones entitled to receive for each licensed product.
Options to purchase ordinary shares.
Vesting period of share awards.
Upfront payments received
Upfront Payment Received
Contingent payments entitled to receive for achievement of research and development milestones
Collaborative Arrangement Research And Development Milestones Entitled To Receive For Each Licensed Product
Options to purchase ordinary shares
Options To Purchase Ordinary Shares
Ordinary shares vesting period
Vesting Period Of Share Awards
Fair value of options.
Fair value of options
Fair Value Of Options
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis]
Deferred revenue, estimated performance period
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
Fair value of non monetary consideration of intellectual property rights.
Fair value of non monetary consideration of intellectual property rights
Fair Value Of Non Monetary Consideration Of Intellectual Property Rights
Revenue recognized
Contract With Customer Liability Revenue Recognized
Due from related parties
Due From Related Parties
Aggregate amount of the transaction price remaining performance obligation
Revenue Remaining Performance Obligation
Number of projects variants.
Benitec agreement .
Benitec Agreement
Benitec Agreement [Member]
Number of project variants
Number Of Project Variants
Collaborative arrangement extended increments term.
Collaborative arrangement additional research term.
Collaborative arrangement extended increments term
Collaborative Arrangement Extended Increments Term
Collaborative arrangement additional research term
Collaborative Arrangement Additional Research Term
Consideration received upon amendment of agreement.
Deferred revenue recognized as upfront payment.
Consideration received upon amendment of agreement
Consideration Received Upon Amendment Of Agreement
Deferred revenue recognized as upfront payment
Deferred Revenue Recognized As Upfront Payment
Collaborative arrangement reimbursements for costs incurred.
Change in collaborative arrangement transaction price.
Collaborative arrangement reimbursements for costs incurred
Collaborative Arrangement Reimbursements For Costs Incurred
Change in collaborative arrangement transaction price
Change In Collaborative Arrangement Transaction Price
Deferred revenue
Deferred Revenue
Remaining performance obligations
Collaborative arrangement contribution upon development milestone.
Choroideremia Research Foundation Agreement.
CRF Agreement
Choroideremia Research Foundation Agreement [Member]
Collaborative arrangement contribution upon development milestone
Collaborative Arrangement Contribution Upon Development Milestone
Maximum contingent payment upon exercise of the option to convert a product.
Development milestone payments.
Development milestone payments relating to Choroideremia.
Collaborative arrangement sales-based milestone payments.
Contingent payment for each nominated product beyond the first three.
Two thousand and seventeen Roche agreement.
2017 Roche Agreement
Two Thousand And Seventeen Roche Agreement [Member]
Contingent payment for each nominated product beyond the first three
Contingent Payment For Each Nominated Product Beyond First Three
Maximum contingent payment upon exercise of the option to convert a product
Maximum Contingent Payment Upon Exercise Of Option To Convert A Product
Development milestone payments
Development Milestone Payments
Development milestone payments relating to Choroideremia
Development Milestone Payments Relating To Choroideremia
Sales-based milestone payments
Collaborative Arrangement Sales Based Milestone Payments
Collaboration arrangements estimated reimbursements for research and development services.
Estimated reimbursements for research and development services
Collaboration Arrangements Estimated Reimbursements For Research And Development Services
Collaborative arrangement adjustment to transaction price.
Collaborative arrangement increase of project scope and expected reimbursable costs.
Collaborative arrangement addition of variable consideration.
Increase (decrease) in contract with customer revenue recognized.
Collaborative arrangement adjustment to transaction price
Collaborative Arrangement Adjustment To Transaction Price
Collaborative arrangement increase of project scope and expected reimbursable costs
Collaborative Arrangement Increase Of Project Scope And Expected Reimbursable Costs
Collaborative arrangement addition of variable consideration
Collaborative Arrangement Addition Of Variable Consideration
Increase (decrease) in revenue recognized
Increase Decrease In Contract With Customer Revenue Recognized
Revenue recognized
Accounts receivable
Contract With Customer Receivable After Allowance For Credit Loss
Collaborative arrangement achieved milestones.
Collaborative arrangement total amount of award
Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
Collaborative arrangement achieved milestones
Collaborative Arrangement Achieved Milestones
Expected payments percentage to equal actual award received.
Number of installments to pay actual award.
Actual award payment period upon first commercial sale of product.
Collaborative arrangements future sales based milestone payments percentage.
Collaborative arrangements royalties percentage on actual award received.
Expected payments percentage to equal actual award received
Expected Payments Percentage To Equal Actual Award Received
Number of installments to pay actual award
Number Of Installments To Pay Actual Award
Actual award payment period upon first commercial sale of product
Actual Award Payment Period Upon First Commercial Sale Of Product
Future sales-based milestone payments percentage
Collaborative Arrangements Future Sales Based Milestone Payments Percentage
Royalties percentage on actual award received
Collaborative Arrangements Royalties Percentage On Actual Award Received
Continuous period where the Company ceases to develop or commercialize any product.
Continuous period where the Company ceases to develop or commercialize any product
Continuous Period Where Company Ceases To Develop Or Commercialize Any Product
Collaborative arrangement transaction price adjustment.
Collaborative arrangement transaction price adjustment
Collaborative Arrangement Transaction Price Adjustment
Estimated fair value of derivative liability
Derivative Fair Value Of Derivative Liability
Number of projects vector variants granted option to license to development and commercialization.
Number of projects vector variants granted option to license to development and commercialization
Number Of Projects Vector Variants Granted Option To License To Development And Commercialization
Collaborative arrangement, extend additional research term.
Collaborative arrangement, projects expires on conclusion of research phase.
Collaborative arrangement, extend additional research term
Collaborative Arrangement Extend Additional Research Term
Collaborative arrangement, projects expires on conclusion of research phase
Collaborative Arrangement Projects Expires On Conclusion Of Research Phase
Non-refundable license fee payable upon execution.
Amount obligated to pay upon closing first qualified financing at option.
Percentage of equity interest upon closing first qualified financing at option.
Non-refundable license fee payable upon execution every year after execution.
Percentage of equity interests issued as common stock.
Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]
Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]
Research and Development Arrangement, Contract to Perform for Others, Type
Research And Development Arrangement Contract To Perform For Others By Type [Axis]
Research and Development Arrangement, Contract to Perform for Others, Type
Research And Development Arrangement Contract To Perform For Others Type [Domain]
UC Agreements.
UC Agreements
U C Agreements [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Non-refundable license fee payable upon execution
Non Refundable License Fee Payable Upon Execution
Non-refundable license fee payable upon execution every year thereafter until sales of a licensed product and payment of royalties
Non Refundable License Fee Payable Every Year After Execution
Amount obligated to pay upon closing first qualified financing at option of UC Regents
Amount Obligated To Pay Upon Closing First Qualified Financing At Option
Percentage of equity interest upon closing first qualified financing at option of UC Regents
Percentage Of Equity Interest Upon Closing First Qualified Financing At Option
Percentage of equity interests issued as common stock
Percentage Of Equity Interests Issued As Common Stock
Amount obligated to pay a non-refundable license fee annually.
Amount paid non-refundable license fee.
Amount paid non-refundable license fee
Amount Paid Non Refundable License Fee
Non-refundable license fee payable annually
Amount Obligated To Pay Non Refundable License Fee Annually
Annual royalty.
Development milestones.
Development milestones
Development Milestones
Annual royalty
Annual Royalty
Incurred expenses
Incurred expenses
Incurred Expenses
Tenant lease improvement, allowance.
Operating lease term extended expiration period.
Commitment and contingencies.
Commitment and contingencies.
Commitment And Contingencies [Table]
Commitment And Contingencies [Table]
Other Assets [Member]
Other Assets [Member]
Accrued and other current liabilities.
Accrued And Other Current Liabilities
Accrued And Other Current Liabilities [Member]
Commitment And Contingencies [Line Items]
Commitment And Contingencies [Line Items]
Lease extended term date
Lease Expiration Date1
Tenant improvement allowance
Tenant Lease Improvement Allowance
Lease extended term period
Operating Lease Term Extended Expiration Period
Lease initial term
Lessor Operating Lease Term Of Contract
Lease option to renew term description
Lessee Operating Lease Option To Extend
Lease existence of option to renew term
Lessee Operating Lease Existence Of Option To Extend
Lease renewal term
Lessee Operating Lease Renewal Term
Percentage of annual rent escalations.
Annual rent
Operating Lease Expense
Percentage of annual rent escalation
Percentage Of Annual Rent Escalations
Deferred rent
Deferred Rent Credit
Security deposit
Security Deposit
2021
Lessee Operating Lease Liability Payments Due Next Twelve Months
2022
Lessee Operating Lease Liability Payments Due Year Two
2023
Lessee Operating Lease Liability Payments Due Year Three
2024
Lessee Operating Lease Liability Payments Due Year Four
2025
Lessee Operating Lease Liability Payments Due Year Five
2026 and beyond
Lessee Operating Lease Liability Payments Due After Year Five
Total
Lessee Operating Lease Liability Payments Due
Accrual related to estimated settlement of claim
Litigation Reserve
Federal statutory income tax rate
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
Research tax credit
Effective Income Tax Rate Reconciliation Tax Credits
Permanent differences
Effective Income Tax Rate Reconciliation Nondeductible Expense
Valuation allowance
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
Provision for income taxes
Effective Income Tax Rate Continuing Operations
Deferred Tax Assets
Deferred Tax Assets Net [Abstract]
Net operating loss carryforwards
Deferred Tax Assets Operating Loss Carryforwards
Other accrued liabilities
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
Deferred revenue
Deferred Tax Assets Deferred Income
Research tax credits
Deferred Tax Assets Tax Credit Carryforwards
Stock compensation
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
Intangible asset basis
Deferred Tax Assets Goodwill And Intangible Assets
Total deferred tax assets
Deferred Tax Assets Gross
Less: valuation allowance
Deferred Tax Assets Valuation Allowance
Net deferred tax assets
Deferred Tax Assets Net
Operating Loss Carryforwards [Table]
Operating Loss Carryforwards [Table]
Income Tax Authority
Income Tax Authority [Axis]
Income Tax Authority
Income Tax Authority [Domain]
Federal
Domestic Country [Member]
State
State And Local Jurisdiction [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards [Line Items]
Increase in valuation allowance, deferred tax asset
Valuation Allowance Deferred Tax Asset Change In Amount
Operating loss carryforwards expiration year.
Net operating loss carryforwards
Operating Loss Carryforwards
Net operating loss carryforwards, expiration year
Operating Loss Carryforwards Expiration Year
Net operating loss carryforward indefinitely
Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration
Tax credit carryforward expiration description.
Tax credit carryforward beginning expiration year.
Research and development credit carryforward
Deferred Tax Assets Tax Credit Carryforwards Research
Tax credit carryforward, expiration description
Tax Credit Carryforward Expiration Description
Tax credit carryforward beginning expiration year
Tax Credit Carryforward Beginning Expiration Year
Net operating loss carryforwards expected to expire unutilized.
NOLS expected to expire unutilized
Net Operating Loss Carryforwards Expected To Expire Unutilized
Balance at beginning of year
Unrecognized Tax Benefits
Additions for current year tax positions
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
Additions for tax positions of prior years
Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
Balance at end of year
Accrued interest and penalties related to unrecognized tax benefits
Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
CARES Act Relief description.
CARES Act, relief description
C A R E S Act Relief Description
Temporary Equity By Class Of Stock [Table]
Temporary Equity By Class Of Stock [Table]
Series C Redeemable Convertible Preferred Stock.
Series C Redeemable Convertible Preferred Stock
Series C Redeemable Convertible Preferred Stock [Member]
Series B redeemable convertible preferred stock.
Series B Redeemable Convertible Preferred Stock
Series B Redeemable Convertible Preferred Stock [Member]
Redeemable Convertible Preferred Stock
Redeemable Convertible Preferred Stock [Member]
Funding Agreement Product.
Funding Agreement Product
Funding Agreement Product [Member]
Temporary Equity [Line Items]
Temporary Equity [Line Items]
Preferred stock, authorized
Preferred stock, par value per share
Series A redeemable convertible preferred stock.
Series A Redeemable Convertible Preferred Stock
Series A Redeemable Convertible Preferred Stock [Member]
Series A-1 redeemable convertible preferred stock.
Series A-1 Redeemable Convertible Preferred Stock
Series A1 Redeemable Convertible Preferred Stock [Member]
Shares Authorized
Original Issuance Price
Share Price
Shares Issued
Shares Outstanding
Liquidation Value
Proceeds Net of Issuance Cost
Temporary equity, shares issued
Temporary equity, shares issued price per share
Net proceeds from issuance of convertible preferred stock
Redeemable convertible preferred stock, conversion basis
Convertible Preferred Stock Settlement Terms
Minimum gross proceeds from IPO for automatic conversion to common stock.
Minimum gross proceeds from IPO for automatic conversion to common stock
Minimum Gross Proceeds From I P O For Automatic Conversion To Common Stock
Redeemable convertible preferred stock, terms of conversion
Convertible Preferred Stock Terms Of Conversion
Redeemable convertible preferred stock dividend declared
Dividends Payable Current And Noncurrent
Additional funding committed.
Investment in redeemable convertible preferred stock financing
Sale Of Stock Consideration Received On Transaction
Additional funding upon acceptance of investigational New Drug application
Additional Funding Committed
Schedule Of Stock By Class [Table]
Schedule Of Stock By Class [Table]
Title of Individual
Title Of Individual [Axis]
Title of Individual
Title Of Individual With Relationship To Entity [Domain]
Founder.
Founder
Founder [Member]
Award Type
Award Type [Axis]
Award Type
Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]
Restricted Common Stock
Restricted Stock [Member]
Class Of Stock [Line Items]
Class Of Stock [Line Items]
Common stock voting rights
Common Stock Voting Rights
Common stock dividend
Dividends Common Stock
Common Stock Warrants
Warrant [Member]
Options Issued and Outstanding
Employee Stock Option [Member]
Employee Stock Share Purchase Plan
Employee Stock [Member]
Plan Name
Plan Name [Axis]
Plan Name
Plan Name [Domain]
Two thousand fifteen equity incentive plan.
2015 Equity Incentive Plan
Two Thousand Fifteen Equity Incentive Plan [Member]
Two thousand twenty equity incentive plan.
2020 Equity Incentive Plan
Two Thousand Twenty Equity Incentive Plan [Member]
Common stock reserved
Common Stock Capital Shares Reserved For Future Issuance
Stock issued
Stock Issued During Period Shares Restricted Stock Award Gross
Shares vested upon issuance
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
Common stock remained subject to repurchase
Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Two thousand twenty incentive award plan.
2020 Incentive Award Plan
Two Thousand Twenty Incentive Award Plan [Member]
Two thousand twenty employee stock purchase plan.
2020 ESPP
Two Thousand Twenty Employee Stock Purchase Plan [Member]
Employee.
Employee
Employee [Member]
Nonemployee.
Nonemployee
Nonemployee [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares reserved for issuance
Options exercisable period
Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
Number of shares available for grant
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
Minimum percentage of outstanding shares held by individual
Share based compensation arrangement by share based payment award exercise price as percentage of fair market value minimum.
Number of options outstanding
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
Minimum percentage of outstanding shares held by individual
Minimum Percentage Of Outstanding Shares Held By Individual
Exercise price as percentage of fair market value, minimum
Share Based Compensation Arrangement By Share Based Payment Award Exercise Price As Percentage Of Fair Market Value Minimum
Employee purchase price of common stock as percentage of fair market value.
Share based compensation arrangement by share based payment award stock overlapping offering period.
Share based compensation arrangement by share based payment award duration purchase period.
Number of shares authorized and reserved for issuance
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
Employee purchase price of common stock as percentage of fair market value
Employee Purchase Price Of Common Stock As Percentage Of Fair Market Value
Common stock overlapping offering period
Share Based Compensation Arrangement By Share Based Payment Award Stock Overlapping Offering Period
Duration of purchase period
Share Based Compensation Arrangement By Share Based Payment Award Duration Purchase Period
Percentage of maximum contributions of employee's eligible compensation
Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate
Share based compensation arrangement by share based payment award shares available for grant grants in period gross.
Share based compensation arrangement by share based payment award shares available for grant expirations in period.
Share based compensation arrangement by share based payment award shares available for grant forfeitures in period.
Number of Shares Available for Grant, Beginning Balance
Number of Shares Available for Grant, Options authorized
Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
Number of Shares Available for Grant, Options granted
Share Based Compensation Arrangement By Share Based Payment Award Shares Available For Grant Grants In Period Gross
Number of Shares Available for Grant, Options expired
Share Based Compensation Arrangement By Share Based Payment Award Shares Available For Grant Expirations In Period
Number of Shares Available for Grant, Options forfeited
Share Based Compensation Arrangement By Share Based Payment Award Shares Available For Grant Forfeitures In Period
Number of Shares Available for Grant, Ending Balance
Number of Shares Underlying Outstanding Options, Beginning Balance
Number of Shares Underlying Outstanding Options, granted
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
Number of Shares Underlying Outstanding Options, exercised
Number of Shares Underlying Outstanding Options, expired
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
Number of Shares Underlying Outstanding Options, forfeited
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
Number of Shares Underlying Outstanding Options, Ending Balance
Number of Shares Underlying Outstanding Options, Shares exercisable, December 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
Number of Shares Underlying Outstanding Options, Shares vested and expected to vest, December 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
Weighted-Average Exercise Price, Beginning Balance
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
Options granted
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
Options exercised
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
Options expired
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
Options forfeited
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
Weighted-Average Exercise Price, Ending Balance
Weighted-Average Exercise Price, Shares exercisable, December 31,2020
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
Weighted-Average Exercise Price, Shares vested and expected to vest, December 31,2020
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
Weighted-Average Remaining Contractual Term (in years), Outstanding
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
Weighted-Average Remaining Contractual Term (in years), Shares exercisable, December 31,2020
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
Weighted-Average Remaining Contractual Term (in years), Shares vested and expected to vest, December 31,2020
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
Aggregate Intrinsic Value, Outstanding Balance
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
Aggregate Intrinsic Value, Options exercised
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
Aggregate Intrinsic Value, Shares exercisable, December 31,2020
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
Aggregate Intrinsic Value, Shares vested and expected to vest, December 31,2020
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]
Income Statement Location
Income Statement Location [Axis]
Income Statement Location
Income Statement Location [Domain]
Research and Development
Research And Development Expense [Member]
General and Administrative
General And Administrative Expense [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation
Allocated Share Based Compensation Expense
Number of stock options granted
Weighted-average grant date fair value
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
Fair value of options vested
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
Unrecognized stock-based compensation of unvested options
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
Unrecognized stock-based compensation, expected to be recognized over weighted-average period
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
Stock-based compensation expense
Expected term
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
Expected volatility, minimum
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
Expected volatility, maximum
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
Risk-free interest rate, minimum
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
Risk-free interest rate, maximum
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
Expected dividend yield
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
Number of warrants issued.
Warrant expires year.
Class Of Warrant Or Right [Table]
Class Of Warrant Or Right [Table]
Private Placement
Private Placement [Member]
Class of Warrant or Right
Class Of Warrant Or Right [Axis]
Class of Warrant or Right
Class Of Warrant Or Right [Domain]
Series B financing.
Series B Financing
Series B Financing [Member]
Class Of Warrant Or Right [Line Items]
Class Of Warrant Or Right [Line Items]
Number of warrants issued
Number Of Warrants Issued
Exercise price
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
Warrant shares exercisable
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
Additional paid-in-capital upon issuance of the warrant
Adjustments To Additional Paid In Capital Warrant Issued
Proceeds from offering of securities in a private placement
Proceeds From Issuance Of Private Placement
Warrant expiration year
Warrant Expires Year
Fair value of warrant shares
Fair Value Adjustment Of Warrants
Warrant vests over period.
Warrant vesting period
Warrant Vests Over Period
Numerator
Earnings Per Share Reconciliation [Abstract]
Net loss attributable to common stockholders
Net Income Loss Available To Common Stockholders Basic
Denominator
Weighted Average Number Of Shares Outstanding [Abstract]
Weighted-average shares outstanding
Weighted Average Number Of Shares Issued Basic
Less: Weighted-average shares subject to repurchase used in computing net loss per share attributable to common stockholders, basic and diluted
Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic and diluted
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]
Antidilutive Securities
Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]
Antidilutive Securities, Name
Antidilutive Securities Name [Domain]
Options to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
Fair value assumptions change of control payment.
Fair value assumptions probability of change in control event percentage.
Fair value assumptions probability of change in control discount rate.
Derivative [Table]
Derivative [Table]
Derivative [Line Items]
Derivative [Line Items]
Change of control payment
Fair Value Assumptions Change Of Control Payment
Change in control event percentage
Fair Value Assumptions Probability Of Change In Control Event Percentage
Change in control discount rate
Fair Value Assumptions Probability Of Change In Control Discount Rate
Schedule Of Related Party Transactions By Related Party [Table]
Schedule Of Related Party Transactions By Related Party [Table]
Related Party
Related Party Transactions By Related Party [Axis]
Related Party
Related Party [Domain]
Pfizer [Member]
Pfizer
Pfizer [Member]
Co-founder and Chief Scientific Advisor [Member]
David Schaffer, PhD,
Co Founder And Chief Scientific Advisor [Member]
UC Regents.
UC Regents
U C Regents [Member]
Related Party Transaction
Related Party Transaction [Axis]
Related Party Transaction
Related Party Transaction [Domain]
Consulting services.
Consulting Services
Consulting Services [Member]
Sponsored Research Agreements.
SRAs
Sponsored Research Agreements [Member]
Ignite [Member]
Ignite
Ignite [Member]
Related Party Transaction [Line Items]
Related Party Transaction [Line Items]
Related party closing date
Related Party Transaction Date
Convertible preferred stock number of shares converted.
Convertible preferred stock, shares converted
Convertible Preferred Stock Number Of Shares Converted
Number of shares acquired
Sale Of Stock Number Of Shares Issued In Transaction
Shares converted, number of common stock issued
Shares sold, price per share
Sale Of Stock Price Per Share
Number of agreements entered.
Term of agreement.
Related party expenses
Related Party Transaction Expenses From Transactions With Related Party
Number of sponsored research agreements entered
Number Of Agreements Entered
Agreement term
Term Of Agreement
Amount due to related party
Due To Related Parties Current And Noncurrent
Payment to related party
Related Party Costs
Accounts payable, related party
Accounts Payable Related Parties Current And Noncurrent
Defined Contribution Plan [Table]
Defined Contribution Plan [Table]
Retirement Plan Name
Retirement Plan Name [Axis]
Retirement Plan Name
Retirement Plan Name [Domain]
Two thousand fourteen plan.
2014 Plan
Two Thousand Fourteen Plan [Member]
Defined Contribution Plan Disclosure [Line Items]
Defined Contribution Plan Disclosure [Line Items]
Employer contribution
Defined Contribution Plan Employer Discretionary Contribution Amount